ClinicalTrials.gg
RecruitingNCT04696081AFIB-CANCERUpdated Aug 9, 2024

Atrial Fibrillation in Active Cancer Patients

An observational study in Cancer, Drug Toxicity and Atrial Fibrillation, sponsored by University Hospital, Caen. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-09.

Sponsored by University Hospital, Caen · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Started Sep 2021; still recruiting 5 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Study summary

Atrial fibrillation is a common complication of both cancer and anticancer drugs but the consequences of such events remain poorly known and are not adressed in both phase III oncological trials and cardiological guidelines. The objective of this study is to create a prospective multicenter international registry of adult patients with an active cancer and experiencing atrial fibrillation to study major cardiovascular events occurrence during a 1 year follow-up.

02

Conditions studied

  • Cancer
  • Drug Toxicity
  • Atrial Fibrillation
  • Cardiovascular Complication
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 200 across 2,644 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

University Hospital, Caen is the lead sponsor of 515 studies on the registry; 84 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with a cancer will defined as patients with confirmed cancer other than basal-cell or squamous-cell carcinoma of the skin, primary brain tumor, known intracerebral metastases, or acute leukemia.

Active cancer will be defined as cancer that had been diagnosed within the past 6 months or recurrent locally advanced or metastatic cancer, and an anticancer treatment given at the time of enrollment or during 6 months before enrollment (according to Agnelli et al. NEJM 2020).

AF patients will be both patients with incident AF (first AF episode diagnosed after cancer diagnosis) and those with prevalent AF (AF recurrence occurring after cancer diagnosis and a first AF episode prior to cancer diagnosis)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients
  • outpatients or hospitalized patients
  • with a confirmed cancer (other than basal-cell or squamous-cell carcinoma of the skin, primary brain tumor, known intracerebral , or acute leukemia) and an active cancer (defined as cancer that had been diagnosed within the past 6 months or recurrent locally advanced or metastatic cancer, for which anticancer treatment was being given at the time of enrollment or during 6 months before enrollment)
  • at least 1 episode of atrial fibrillation (new onset AF occuring after cancer diagnosis or history of paroxysmal of persistant AF prior to cancer diagnosis and an AF recurrence after cancer diagnosis)
  • in sinus rhythm at the time of cancer diagnosis

Exclusion criteria

Exclusion Criteria:

  • patient with palliative cares or other conditions resulting in short term death (death expected in the month following atrial fibrillation occurrence)
  • history of long-standing persistant or permanent AF prior to cancer diagnosis
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Interventions

  • Otheroccurence of atrial fibrillation

    all adult patients with an active cancer and experiencing atrial fibrillation will be consecutively include. Active cancers will be defined according Agnelli et al. (NEJM 2020; 382:1599-1607).

06

What researchers measure

Primary outcomes

  1. Occurrence of major cardiovascular events and death of any cause at 1 year

    Occurrence of death of any cause, cardiovascular death, heart failure, stroke, myocardial infarction in active cancer patients with atrial fibrillation.

    Time frame: from inclusion in the registry to 1 year of follow-up

Secondary outcomes

  1. Occurrence of major cardiovascular events and death of any cause at 1 year in prevalent and incident AF patients

    Occurrence of death of any cause, cardiovascular death, heart failure, stroke, myocardial infarction in active cancer patients according to the AF type (prevalent or incident).

    Time frame: from inclusion in the registry to 1 year of follow-up

  2. Description of the population of active cancer patients experiencing atrial fibrillation (in both prevalent and incidence AF patients).

    Description of the population of active cancer patients experiencing atrial fibrillation. Active cancers will be defined according Agnelli et al. (NEJM 2020; 382:1599-1607).

    Time frame: at the inclusion in the registry

  3. Description of the management of atrial fibrillation in cancer patients (in both prevalent and incidence AF patients).

    Description of the management (anticoagulants, rhythm or rate control) of atrial fibrillation in cancer patients

    Time frame: from inclusion in the registry to 1 year of follow-up

  4. Description of the population of active cancer patients having a major cardiovascular event

    Description of the population of patients having a major cardiovascular event among cancer patients experiencing atrial fibrillation

    Time frame: from inclusion in the registry to 1 year of follow-up

  5. Identifying risk factors associated with major cardiovascular events and all cause mortality occurrence

    Identifying risk factors (clinical, EKG, biological, echocardiography) of major cardiovascular events and all cause mortality in cancer patients experiencing atrial fibrillation

    Time frame: from inclusion in the registry to 1 year of follow-up

  6. Identifying factors associated with atrial fibrillation recurrence

    Identifying factors (clinical, EKG, biological, echocardiography) of atrial fibrillation recurrence in cancer patients

    Time frame: from inclusion in the registry to 1 year of follow-up

  7. Occurrence of major and clinically relevant non-major bleedings (2005 ISTH definition)

    Occurrence of major and clinically relevant non-major bleedings in active cancer patients experiencing atrial fibrillation.

    Time frame: from inclusion in the registry to 1 year of follow-up

  8. Identifying risk factors associated with major and clinically relevant non-major bleedings (2005 ISTH definition)

    Identifying risk factors (clinical, EKG, biological, echocardiography) of major and clinically relevant non-major bleedings in active cancer patients experiencing atrial fibrillation

    Time frame: from inclusion in the registry to 1 year of follow-up

07

Study locations

1 of 1 sites recruiting
  • Alexandre
    Caen, Normandy 14000, France
    Recruiting
08

References and documents

Publications

  • Alexandre J, Moslehi JJ, Bersell KR, Funck-Brentano C, Roden DM, Salem JE. Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms. Pharmacol Ther. 2018 Sep;189:89-103. doi: 10.1016/j.pharmthera.2018.04.009. Epub 2018 Apr 24. PubMed 29698683 ↗
  • Alexandre J, Salem JE, Moslehi J, Sassier M, Ropert C, Cautela J, Thuny F, Ederhy S, Cohen A, Damaj G, Vilque JP, Plane AF, Legallois D, Champ-Rigot L, Milliez P, Funck-Brentano C, Dolladille C. Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database. Eur Heart J Cardiovasc Pharmacother. 2021 Jul 23;7(4):312-320. doi: 10.1093/ehjcvp/pvaa037. PubMed 32353110 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2021 (actual). Primary completion is estimated for Sep 2025, 48 months after the start.

Of 1,099 non-industry observational studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 227. This study's planned 48 months is below that.

Counting every sponsor, half of 1,247 studies reached it within 58 months; a quarter within 24 and three quarters within 210.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2021
First posted
Jan 6, 2021
StartActual
Sep 1, 2021
Primary completionEst.
Sep 1, 2025
CompletionEst.
Jan 1, 2026
Last update
Aug 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04696081
Collaborators
University Hospital, Marseille, France, Hospices Civils de Lyon, France, Centre Francois Baclesse, Caen, France, University Hospital of Saint-Etienne, France, Hôpital Lariboisière Fernand Widal, Paris, France, Institut de Cancérologie de l'Ouest Nantes, France, Fundacion Cardio Onco, Santiago, Chile, Hunter New England Area Health Service, University of Newcastle, Australia, University Hospital, Rouen
Responsible party
Sponsor
First posted
Jan 6, 2021
Start date
Sep 1, 2021
Primary completion
Sep 1, 2025 (estimated)
Completion
Jan 1, 2026 (estimated)
Last update
Aug 9, 2024

Study contacts

Joachim Alexandre, MD, PhD
Contact
alexandre-j@chu-caen.fr
+330231064770
Joachim Alexandre, MD, PhD
principal investigator · Caen Normandy University Hospital, France

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion